Л. Б. Дробот

1.4k total citations
52 papers, 801 citations indexed

About

Л. Б. Дробот is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Л. Б. Дробот has authored 52 papers receiving a total of 801 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 10 papers in Cell Biology and 9 papers in Oncology. Recurrent topics in Л. Б. Дробот's work include Protein Kinase Regulation and GTPase Signaling (10 papers), Cell Adhesion Molecules Research (8 papers) and Fullerene Chemistry and Applications (7 papers). Л. Б. Дробот is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (10 papers), Cell Adhesion Molecules Research (8 papers) and Fullerene Chemistry and Applications (7 papers). Л. Б. Дробот collaborates with scholars based in Ukraine, United Kingdom and Germany. Л. Б. Дробот's co-authors include Vladimir L. Buchman, Ivan Gout, Valeriy Filonenko, Natalia Ninkina, Michael D. Waterfield, Svitlana Prylutska, Alun M. Davies, Jimi Adu, Gayle Middleton and Olga Matyshevska and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Л. Б. Дробот

44 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Л. Б. Дробот Ukraine 17 485 155 110 105 100 52 801
Isabel Serrano Spain 11 589 1.2× 199 1.3× 130 1.2× 155 1.5× 155 1.6× 14 856
Bert Grobben Belgium 12 461 1.0× 72 0.5× 100 0.9× 70 0.7× 60 0.6× 15 977
Christin Karlsson Sweden 11 711 1.5× 113 0.7× 182 1.7× 225 2.1× 73 0.7× 18 1.1k
Marcella Debidda United States 13 488 1.0× 156 1.0× 221 2.0× 165 1.6× 72 0.7× 13 857
Byung‐Gyu Kim South Korea 21 732 1.5× 69 0.4× 121 1.1× 201 1.9× 56 0.6× 44 1.0k
Christine Y. Chuang Denmark 19 441 0.9× 252 1.6× 41 0.4× 144 1.4× 58 0.6× 46 1.1k
Yihan Wang China 14 454 0.9× 64 0.4× 48 0.4× 98 0.9× 31 0.3× 33 640
Ewa Marcinkowska Poland 24 746 1.5× 126 0.8× 155 1.4× 89 0.8× 112 1.1× 71 1.3k
İbrahim Tekedereli Türkiye 14 567 1.2× 79 0.5× 114 1.0× 155 1.5× 46 0.5× 39 970

Countries citing papers authored by Л. Б. Дробот

Since Specialization
Citations

This map shows the geographic impact of Л. Б. Дробот's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Л. Б. Дробот with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Л. Б. Дробот more than expected).

Fields of papers citing papers by Л. Б. Дробот

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Л. Б. Дробот. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Л. Б. Дробот. The network helps show where Л. Б. Дробот may publish in the future.

Co-authorship network of co-authors of Л. Б. Дробот

This figure shows the co-authorship network connecting the top 25 collaborators of Л. Б. Дробот. A scholar is included among the top collaborators of Л. Б. Дробот based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Л. Б. Дробот. Л. Б. Дробот is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tykhomyrov, А. A., Svitlana Prylutska, В. В. Черепанов, et al.. (2023). Antimetastatic lung cancer therapy using alkaloid Piperlongumine noncovalently bound to С60 fullerene. Journal of Drug Delivery Science and Technology. 92. 105275–105275. 1 indexed citations
3.
Дробот, Л. Б., et al.. (2022). Rhabdomyolysis attenuates activity of semicarbazide sensitive amine oxidase as the marker of nephropathy in diabetic rats. SHILAP Revista de lepidopterología. 94(1). 23–32. 3 indexed citations
5.
Prylutska, Svitlana, Maxim P. Evstigneev, Л. Б. Дробот, et al.. (2021). Nanocomplex of Berberine with C60 Fullerene Is a Potent Suppressor of Lewis Lung Carcinoma Cells Invasion In Vitro and Metastatic Activity In Vivo. Materials. 14(20). 6114–6114. 10 indexed citations
7.
Mennerich, Daniela, Anatoly Samoylenko, Elitsa Y. Dimova, et al.. (2019). The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2. Cancer Research. 79(16). 4042–4056. 9 indexed citations
8.
Дробот, Л. Б., et al.. (2018). Adaptor protein Ruk/CIN85 modulates resistance to doxorubicin of murine 4T1 breast cancer cells. The Ukrainian Biochemical Journal. 90(3). 94–100. 2 indexed citations
9.
Prylutska, Svitlana, et al.. (2017). Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects. Nanoscale Research Letters. 12(1). 40–40. 53 indexed citations
10.
Комісаренко, С. В., et al.. (2016). Transcriptional regulation of NOX genes expression in human breast adenocarcinoma MCF-7 cells is modulated by adaptor protein Ruk/CIN85. The Ukrainian Biochemical Journal. 88(1). 119–125. 4 indexed citations
11.
Samoylenko, Anatoly, et al.. (2014). Multiple molecular forms of adaptor protein Ruk/CIN85 specifically associate with different subcellular compartments in human breast adenocarcinoma MCF-7 cells. The Ukrainian Biochemical Journal. 86(5). 102–110. 1 indexed citations
12.
Samoylenko, Anatoly, Nadiya Byts, Valeriy V. Lyzogubov, et al.. (2012). Increased levels of the HER1 adaptor protein Ruk l /CIN85 contribute to breast cancer malignancy. Carcinogenesis. 33(10). 1976–1984. 28 indexed citations
13.
Steelman, Linda S., Patrick M. Navolanic, William H. Chappell, et al.. (2011). Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 10(17). 3003–3015. 70 indexed citations
14.
Skrypkina, Inessa, Oleksandr Dergai, Liudmyla Tsyba, et al.. (2011). Identification and characterization of a novel mammalian isoform of the endocytic adaptor ITSN1. Gene. 485(2). 120–129. 12 indexed citations
15.
Tossidou, Irini, Beina Teng, Л. Б. Дробот, et al.. (2010). CIN85/RukL Is a Novel Binding Partner of Nephrin and Podocin and Mediates Slit Diaphragm Turnover in Podocytes. Journal of Biological Chemistry. 285(33). 25285–25295. 50 indexed citations
16.
Samoylenko, Anatoly, et al.. (2010). The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1α. Thrombosis and Haemostasis. 103(5). 901–909. 4 indexed citations
17.
Samoylenko, Anatoly, et al.. (2009). Protein kinase D interacts with adaptor protein Ruk/CIN85 and phosphorylates it. SHILAP Revista de lepidopterología. 3(3). 17–28. 2 indexed citations
18.
Boretsky, Yuriy R., et al.. (2005). Positive selection of mutants defective in transcriptional repression of riboflavin synthesis by iron in the flavinogenic yeast. FEMS Yeast Research. 5(9). 829–837. 18 indexed citations
20.
Kit, Yu. Ya., Viktor R. Drel, Oleh I. Petriv, et al.. (2003). Adaptor Protein Ruk1 Forms Protein–Protein Complexes with Endonuclease Activity in HEK293 Cells. Biochemistry (Moscow). 68(7). 810–815. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026